Bruce Baker, DO
Obesity Medicine · Puyallup, WANPI 1518079722
Payments from drug & device makers
Across 202 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$648
- Novo Nordisk$600
- Bayer$546
- AbbVie$345
- GSK$260
- Takeda Pharmaceuticals U.S.A., Inc.$252
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,20299%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $648 |
| Novo Nordisk | 35 | $600 |
| Bayer | 19 | $546 |
| AbbVie(2 entities) | 13 | $345 |
| GSK | 11 | $260 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $252 |
| Revance Therapeutics, Inc. | 5 | $251 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $210 |
| AstraZeneca | 9 | $186 |
| Corcept Therapeutics | 6 | $154 |
| Johnson & Johnson | 4 | $133 |
| Pfizer | 7 | $132 |
| Abbott | 5 | $97 |
| Boehringer Ingelheim | 4 | $78 |
| Galderma Laboratories, L.p. | 4 | $73 |
| Exact Sciences | 2 | $58 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| Dexcom, Inc. | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Vertex | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Linus Health, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$115
How this compares
Too few obesity medicine providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $72,068 |
| EliquisApixaban | 38 | $44,175 |
| MounjaroTirzepatide | 31 | $41,634 |
| TrulicityDulaglutide | 22 | $34,737 |
| JardianceEmpagliflozin | 25 | $23,206 |
| XareltoRivaroxaban | 17 | $22,624 |
| JanuviaSitagliptin Phosphate | 17 | $17,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,565 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,105 |
| Atorvastatin Calcium | 231 | $2,236 |
| Levothyroxine Sodium | 173 | $1,629 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,308 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 109 | $1,300 |
| Metoprolol Succinate | 58 | $1,262 |
| Omeprazole | 98 | $1,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $648 | $76,37153 claims |
| Novo NordiskOzempic | $600 | $72,06867 claims |
| PfizerEliquis | $132 | $44,17538 claims |
| Boehringer IngelheimJardiance | $78 | $23,20625 claims |
| Johnson & JohnsonXarelto | $133 | $22,62417 claims |
| GSKTrelegy Ellipta | $260 | $11,56519 claims |
| AbbVieSynthroid | $345 | $1,06012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Washingtonon file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Puyallup
- Richard LindquistSeattle$9K
- Nicole PatchingWalla Walla$576
- Poornima RamadasKirkland$554
- Angela ZechmannOlympia$492
- Michelle RappaportSeattle$419
- Karyn HarkinsTacoma$46
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.